|
|
News Breaks | | | | February 11, 2013 | | 08:29 EDT |  | SRPT | Sarepta's eteplirsen accelerated approval could be denied, TheStreet.com reports
According to TheStreet.com, accelerated approval for Sarepta's (SRPT) eteplirsen, a novel experimental drug for Duchenne Muscular Dystrophy, will be denied by the FDA. Instead, TheStreet says it is more likely Sarepta will be required to perform a larger pivotal study prior to submitting the drug for FDA review. Reference Link | |
|
News For SRPT From The Last 14 Days Check below for free stories on SRPT the last two weeks. |
|
|
| May 21, 2013 | | 07:34 EDT |  | SRPT | UBS to host a conference
 Subscribe for More Information | | | May 16, 2013 | | 07:29 EDT | | SRPT | Leerink to host a bus tour
Boston Biopharma Bus Tour travels throughout Boston on May 16-17. | | | May 9, 2013 | | 12:21 EDT |  | SRPT | Sarepta climbs after saying documents to be submitted this month
Subscribe for More Information | | | 07:29 EDT |  | SRPT | Sarepta reports Q1 EPS (41c), consensus (62c)
Reports Q1 revenue $4.5M, consensus $5.85M. | |
|
|
|
|
|
|
